Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | DUT | P33316 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21523562 | 0.98 | HTR2C (0.47) | HTR2CHTR2BHTR2ADUTCSNK2A1 | |
| Hydrochloric Acid SCHEMBL20187737 | 0.85 | HTR2C (0.44) | HTR2CHTR2BHTR2ADUTPDE4B | |
| SCHEMBL20208255 | 0.84 | DUT (0.42) | HTR2CHTR2BHTR2ADUTGRM2 | |
| SCHEMBL20188035 | 0.84 | CYP4F2 (0.50) | HTR2CHTR2BHTR2ADUTGRM2 | |
| SCHEMBL31220910 | 0.82 | NUDT1 (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL24180175 | 0.80 | DUT (0.40) | HTR2CHTR2BHTR2ADUTGRM2 | |
| SCHEMBL22392894 | 0.80 | RIPK1 (0.52) | HTR2CHTR2BHTR2ADUTGRM2 | |
| SCHEMBL28844733 | 0.80 | HTR2C (0.43) | HTR2CHTR2BHTR2AGRM2 | |
| SCHEMBL15711346 | 0.79 | PDE4B (0.56) | HTR2CHTR2BHTR2APDE4B | |
| SCHEMBL2954077 | 0.79 | PDE4B (0.54) | HTR2CHTR2BHTR2APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673908-B1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3673908-B1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3673908-A1 | ANTI-TUMOR EFFECT POTENTIATOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-07-01 | — | — | EP | disclosed |
| EP-2508185-B1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-2508185-B1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-8883759-B2 | Anti-tumor effect potentiator | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883759-B2 | Anti-tumor effect potentiator | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883759-B2 | Anti-tumor effect potentiator | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| WO-2011065541-A1 | ANTI-TUMOR EFFECT POTENTIATOR | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011065545-A1 | 5-FLUOROURACIL COMPOUND HAVING dUTPase-INHIBITING ACTIVITY OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009147843-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | CCNT1, CCNA1, UPP1 | HTR2C 4589/4885HTR2B 4618/4885HTR2A 4476/4885 |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | HTR2C 3450/4885HTR2B 3922/4885HTR2A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.